利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

91 条记录 (耗时 0.045 秒)

    LACTIC ACID BACTERIAL STRAINS
    5.
    发明申请
    LACTIC ACID BACTERIAL STRAINS 有权

    公开(公告)号：US20220080003A1

    公开(公告)日：2022-03-17

    申请号：US17232871

    申请日：2021-04-16

    申请人： 4D Pharma Research Limited

    发明人： Denise Kelly

    IPC分类号： A61K35/747 ,  A23L33/135 ,  C12N1/20 ,  A23K10/18

    摘要： A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against E. coli; (ii) the ability to exhibit antimicrobial activity against S. enteritidis; (iii) the ability to suppress inflammation in IPEC cells induced by 12-O-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by S. enteritidis; (v) the ability to block the attachment or invasion of IPEC cells by E. coli; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70° C. for a period of 15 minutes. Further aspects of the invention relate to compositions comprising said bacterial strains, and therapeutic uses of said bacterial strains.

    Lactic acid bacterial strains
    9.
    发明授权
    Lactic acid bacterial strains 有权

    公开(公告)号：US11013773B2

    公开(公告)日：2021-05-25

    申请号：US16206250

    申请日：2018-11-30

    申请人： 4D Pharma Research Limited

    发明人： Denise Kelly

    IPC分类号： A61K35/747 ,  A23L33/135 ,  C12R1/225 ,  C12R1/23 ,  C12R1/25 ,  C12N1/20 ,  A23K10/18

    摘要： A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against E. coli; (ii) the ability to exhibit antimicrobial activity against S. enteritidis; (iii) the ability to suppress inflammation in IPEC cells induced by 12-0-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by S. enteritidis; (v) the ability to block the attachment or invasion of IPEC cells by E. coli; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70° C. for a period of 15 minutes. Further aspects of the invention relate to compositions comprising said bacterial strains, and therapeutic uses of said bacterial strains.